San Francisco, 2
November 2018: The global monoclonalantibodies (mAbs) market was
valued at USD 85.4 billion in 2015 and is expected to reach a value of USD
138.6 billion by 2024. Increasing R&D pertaining to the development of
therapeutic mAbs coupled with supportive government initiatives is expected to
drive the monoclonal antibodies market growth over the forecast period.
Increasing demand for personalized medicine
is a vital factor responsible for the increasing development of therapeutic
antibodies to provide targeted therapies as every individual responds in a
different manner to a particular treatment. Moreover, related benefits of using
mAbs for therapeutic purposes, including fewer adverse effects, homogeneity,
specificity, and large-scale production, are contributing toward significant
market growth.
In addition, the government initiatives to
enable cost-effective production of mAbs is anticipated to propel the emergence
of this sector over the forecast period. For instance, the biomanufacturing
initiative byNational Institute of Standards and Technology in the U.S.
provides scientifically sound regulatory guidelines to ensure effective and
safe manufacturing of protein therapeutics and to support biopharmaceutical
manufacturers in offering low-cost and high-quality protein drugs across the
globe.
Access Research Report
of Monoclonal Antibodies (mAbs) Market @ www.grandviewresearch.com/industry-analysis/monoclonal-antibodies-market
Further Key Findings from the Study Suggest:
· Human-based mAbs segment is predicted to
grow at a lucrative CAGR in the coming years due to their associated benefits
and numerous R&D activities conducted for further development of human
mAbs. Large number of mAbs of human origin are in phase III clinical trial for
cancer treatment
· In vitro production of mAbs is anticipated
to show the fastest growth owing to its wide-scale adoption by biologics
manufacturers due to its greater efficiency in cost and time
· The research institute segment is
anticipated to exhibit profitable growth due to increasing R&D efforts in
the biotech industry as monoclonal antibodies have emerged as a major class of
therapeutics for several human diseases, particularly immunological infectious
diseases and cancer
· The Asia pacific region has significant
growth potential due to rising government initiatives in this region supporting
the use of mAbs for research and treatment purposes coupled with the surge in
sponsored R&D projects for the development of cost-effective therapeutic
mAbs.
· For instance, government-led fund
providers, such as National Natural Science Foundation and National Basic
Research Program of China, offer financial support to enterprises and
universities to conduct mAb research and development.
· The key players serving the monoclonal
antibodies market arePfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck
& Co., Inc, Amgen, Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and
Company, Mylan N.V., Daiichi Sankyo Company, Ltd., Bayer AG, Bristol Myers
Squibb Co.,Johnson & Johnson Services, Inc., Biogen Inc., Thermo Fisher
Scientific, Inc., Sanofi Genzyme, F. Hoffmann-La Roche Ltd., and Novo Nordisk
A/S.
· The introduction of advanced methods for
mAb production further encourages the pharmaceutical companies to build their
own product pipeline. According to a study published by NCBI at the end of
2013, approximately 816 companies were involved in therapeutic protein
research.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the
monoclonal antibodies market by source type, production, indication, end-use,
and region:
Global Monoclonal Antibodies Source
Type Outlook (Revenue, USD Billion, 2013 - 2024)
·
Murine
·
Chimeric
·
Humanized
·
Human
Global Monoclonal Antibodies Production
Type Outlook (Revenue, USD Billion, 2013 - 2024)
·
In Vivo
·
In Vitro
Global Monoclonal Antibodies Indication
Outlook (Revenue, USD Billion, 2013 - 2024)
·
Cancer
·
Autoimmune Diseases
·
Inflammatory Diseases
·
Infectious Diseases
·
Microbial Diseases
·
Others
Global Monoclonal Antibodies End-use
Outlook (Revenue, USD Billion, 2013 - 2024)
·
Hospitals
·
Research Institutes
·
Others
Monoclonal antibodies Market Regional
Outlook (Market Revenue in USD Billion, 2013 - 2024)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East and Africa
Access Press Release of
Monoclonal Antibodies (mAbs) Market@ www.grandviewresearch.com/press-release/global-monoclonal-antibodies-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment